89 related articles for article (PubMed ID: 6999559)
1. [Piperazine sultosylate in the treatment of hyperlipidemias].
Balaguer Vintro I; Duarte Mantilla G
Rev Clin Esp; 1980 Jul 15-31; 158(1-2):37-40. PubMed ID: 6999559
[No Abstract] [Full Text] [Related]
2. [Clinical effectiveness of piperazine sultosylate in the hyperlipidemias].
Casellas Bernat A; Ribas Grau M; Casellas Bernat G; Riera de Barcia L; Alou Llado M; Solivellas Antich S
Rev Clin Esp; 1981 Apr; 161(1):5-8. PubMed ID: 7255818
[No Abstract] [Full Text] [Related]
3. [Drug therapy of hyperlipidemic states].
Lipovetskiĭ BM; Triufanov VF; Konstantinov VO
Klin Med (Mosk); 1980 Apr; 58(4):56-61. PubMed ID: 7382369
[No Abstract] [Full Text] [Related]
4. [Therapy of disorders of the lipid metabolism which carry the risk of arteriosclerosis].
Kopp H
MMW Munch Med Wochenschr; 1978 May; 120(21):739-40. PubMed ID: 306554
[No Abstract] [Full Text] [Related]
5. [Hypolipemic activity of piperazine sultosylate (A-585) in the rat and chicken].
Rodríguez L; Roser R; Palacios G; Sagarra R; Esteve A
Arch Farmacol Toxicol; 1979 Dec; 5(3):272-4. PubMed ID: 546353
[No Abstract] [Full Text] [Related]
6. Hyperlipidaemia and cardiovascular disease.
Sussekov AV
Curr Opin Lipidol; 1999 Dec; 10(6):635-9. PubMed ID: 10680059
[No Abstract] [Full Text] [Related]
7. Article: In the absence of dietary surveillance, chitosan does not reduce plasma lipids...(SC Ho, et al)(SMJ Vol 42 Issue 1 January 2001.
Peng LH
Singapore Med J; 2001 May; 42(5):230-1. PubMed ID: 11513064
[No Abstract] [Full Text] [Related]
8. [Treatment of postoperative instrumental forms of crystitis. Controlled study].
Coscia M
Minerva Chir; 1974 Feb; 29(3):146-50. PubMed ID: 4594256
[No Abstract] [Full Text] [Related]
9. [Study of the action of basic aluminium clofibrate on blood lipids and hemostasis].
Edmond E; Daver J; Daver M; Blanchard J; Ricoeur M; Cuong TC
Therapeutique; 1970 Jan; 46(1):55-9. PubMed ID: 4908720
[No Abstract] [Full Text] [Related]
10. Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia.
Burnett JR
IDrugs; 2006 Jul; 9(7):495-9. PubMed ID: 16821163
[TBL] [Abstract][Full Text] [Related]
11. [Study of the therapeutic effect of clofibrate in discontinuous administration].
Cottet J; Cristol R; Loeper J; Debray J
Therapie; 1974; 29(5):675-9. PubMed ID: 4618386
[No Abstract] [Full Text] [Related]
12. [Effect of the administration of silymarin on serum lipid levels].
Petronelli A; Roda E; Briganti M; Morselli Labate AM; Barbara L
Clin Ter; 1981 Dec; 99(5):471-82. PubMed ID: 7333068
[No Abstract] [Full Text] [Related]
13. [Therapy with the sulfated polyanion SP 54].
Weyer H; Muth HW
Med Welt; 1973 May; 24(19):800-2. PubMed ID: 4269029
[No Abstract] [Full Text] [Related]
14. [The clinical pharmacology and efficacy of statins].
Sidorenko BA; Preobrazhenskiĭ DV; Sopoleva IuV
Ter Arkh; 1996; 68(9):80-4. PubMed ID: 9005624
[No Abstract] [Full Text] [Related]
15. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
[TBL] [Abstract][Full Text] [Related]
16. Lipids and their role in coronary heart disease: what they do and how to manage them.
Pradka LR
Nurs Clin North Am; 2000 Dec; 35(4):981-91. PubMed ID: 11072283
[TBL] [Abstract][Full Text] [Related]
17. [Treatment and prevention of hyper- and dyslipidemia with magnesium-containing drugs].
Shilov AM; Sviatov IS; Chubarov MV; Sanodze ID
Klin Med (Mosk); 1998; 76(4):35-7. PubMed ID: 9613080
[No Abstract] [Full Text] [Related]
18. [Therapeutic evaluation of Win 24.933-2 (hidroxymethol derivative of Miracil D) and of A 16.612 (Piperazine compound) in human schistosomiasis mansoni by the quantitative oogram technique].
da Cunha AS; Cançado JR
Rev Inst Med Trop Sao Paulo; 1968; 10(2):118-23. PubMed ID: 4878262
[No Abstract] [Full Text] [Related]
19. [Experience with the hypolipidemic drug Lipanthyl].
Vaverková H; Kubasta M; Zmeskal A; Vrublovský P; Skrabalová H; Vlcek L
Vnitr Lek; 1982 Jul; 28(7):698-704. PubMed ID: 7051538
[No Abstract] [Full Text] [Related]
20. Requirements and methods for documenting diet uniformity and compliance in drug development trials.
Held J
Am J Cardiol; 1998 Apr; 81(8A):31F-33F. PubMed ID: 9604903
[No Abstract] [Full Text] [Related]
[Next] [New Search]
